2. Search Result
Search Result
Results for "

MLKL-IN-1

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144828
    RIP1/RIP3/MLKL activator 1
    2 Publications Verification

    		 RIP kinase Mixed Lineage Kinase Necroptosis Cancer
    RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability [1].
    RIP1/RIP3/MLKL activator 1
  • HY-157039
    RIPK1-IN-17

    		RIP kinase Inflammation/Immunology
    RIPK1/3-IN-17 (Compound 10) is a RIPK1 and RIPK3 inhibitor. RIPK1/3-IN-17 specifically inhibits necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation .
    RIPK1-IN-17
  • HY-100573
    Necrosulfonamide
    80+ Cited Publications

    		 Mixed Lineage Kinase Cancer
    Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis [1].
    Necrosulfonamide
  • HY-100573S
    Necrosulfonamide-d4

    		Mixed Lineage Kinase Cancer
    Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide. Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis [1].
    Necrosulfonamide-d4
  • HY-100573A
    (E/Z)-Necrosulfonamide

    		Mixed Lineage Kinase Cancer
    (E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis [1] .
    (E/Z)-Necrosulfonamide
  • HY-139878
    MLKL-IN-1

    		Mixed Lineage Kinase Inflammation/Immunology
    MLKL-IN-1 is a covalent MLKL inhibitor with a KD of 50 μM.
    MLKL-IN-1
  • HY-156591
    PROTAC MLKL Degrader-1

    		PROTACs Mixed Lineage Kinase Others
    PROTAC MLKL Degrader-1 (Compound 36) is a PROTAC degrader of MLKL, with a Dmax ＞90%. PROTAC MLKL Degrader-1 contains modified CRBN ligands, linker and Lenalidomide (HY-A0003)-linker fragments. PROTAC MLKL Degrader-1 abrogates cell death in a TSZ model of necroptosis.
    PROTAC MLKL Degrader-1
  • HY-162424
    ZBP1/RIP3/MLKL activator 1

    		RIP kinase Mixed Lineage Kinase Necroptosis Cancer
    ZBP1/RIP3/MLKL activator 1 (compound 3a) is a synthetically derived quinoline compound. ZBP1/RIP3/MLKL Activator 1 induces DNA damage, enhances intracellular levels of reactive oxygen species (ROS), and triggers apoptosis via the caspase pathway. Furthermore, when apoptosis is inhibited, ZBP1/RIP3/MLKL Activator 1 promotes necroptotic cell death through the ZBP1-RIP3-MLKL pathway. ZBP1/RIP3/MLKL Activator 1 is utilized in oncological research, particularly in the selective targeting of cells with impaired apoptotic function [1].
    ZBP1/RIP3/MLKL activator 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: